Colchicine: Repositioning an “ancient” medicine in the 21st century DOI Creative Commons
Е. Л. Насонов, О. М. Драпкина

Rheumatology Science and Practice, Journal Year: 2024, Volume and Issue: 62(5), P. 445 - 464

Published: Oct. 31, 2024

The main indications for colchicine treatment until recently were gout, pericarditis, familial Mediterranean fever and some other auto-inflammatory diseases. expansion of (repositioning) the use in direction prevention cardiovascular complications should be considered as one major events medicine XXI century. Deciphering role inflammation most important mechanism development atherosclerosis has created prerequisites concept anti-inflammatory therapy atherosclerosis, which low-dose can take an place, complementing effects aspirin, statins antihypertensive therapy. analysis materials from randomized placebo-controlled studies indicates a decrease frequency patients with coronary heart disease (by 31%) who have suffered myocardial infarction 23%), well 33%), stroke, need revascularization mortality. low dose (0.5 mg/day) is approved by U.S. Food Drug Administration disease. It assumed that future will place pathology associated atherosclerotic vascular

Language: Английский

Future atherosclerotic cardiovascular disease in systemic lupus erythematosus based on CSTAR (XXVIII): the effect of different antiphospholipid antibodies isotypes DOI Creative Commons
Can Huang, Yufang Ding, Zhen Chen

et al.

BMC Medicine, Journal Year: 2025, Volume and Issue: 23(1)

Published: Jan. 6, 2025

Patients with systemic lupus erythematosus (SLE) suffered from an increasing risk of cardiovascular diseases. In this multi-center prospective study, we aimed to determine the association between antiphospholipid antibodies (aPLs) and future atherosclerotic disease (ASCVD) in SLE. total, 1573 SLE patients were recruited based on Chinese Treatment Research group (CSTAR) registry. aPLs profile, including anticardiolipin (aCL) IgG/IgM, anti-β2 glycoprotein I (aβ2GPI) anticoagulant (LA), measured each center. Future ASCVD events defined as new-onset myocardial infarction, stroke, artery revascularization, or death. Among patients, 525 (33.4%) had positive aPLs. LA highest prevalence (324 [20.6%]), followed by aCL IgG (249 [15.8%]), aβ2GPI (199 [12.7%]). 116 (7.37%) developed during mean follow-up 4.51 ± 2.32 years 92 positive. univariate Cox regression analysis, both (HR = 7.81, 95% CI 5.00–12.24, p < 0.001) traditional factors associated events. multiple 1.95, 1.25–3.00, 0.003), IgM 1.83, 1.03–3.20, 0.039), 5.13, 3.23–8.20, positivity remained ASCVD; for ASCVD, smoking, gender, age hypertension, also play independent role patients. More importantly, Aspirin can reduce 0.57 CI, 0.25–0.93, P 0.026). aPLs, especially IgG/IgM LA, warrant more care surveillance follow-up. may have a protective effect ASCVD.

Language: Английский

Citations

2
Atherosclerosis and the Bidirectional Relationship Between Cancer and Cardiovascular Disease: From Bench to Bedside, Part 2 Management DOI Open Access

Giuseppina Gallucci,

Mario Larocca, Alessandro Navazio

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(1), P. 334 - 334

Published: Jan. 2, 2025

The first part of this review highlighted the evolving landscape atherosclerosis, noting emerging cardiometabolic risk factors, growing impact exposomes, and social determinants health. prominent role atherosclerosis in bidirectional relationship between cardiovascular disease cancer was also discussed. In second part, we examine complex interplay multimorbid cardio-oncologic patients, harmful environments that lend a “syndemic” nature to these chronic diseases. We summarize management strategies targeting disordered factors mitigate explore molecular mechanisms enabling more tailored therapies. Importantly, emphasize early interception through multifactorial interventions detect subclinical signs (via biomarkers imaging) treat modifiable prevent clinical events. A concerted preventive effort—referred by some as “preventome”—is essential reduce burden atherosclerosis-driven diseases, shifting from mere proactive promotion “chronic health”.

Language: Английский

Citations

1
In Situ Conversion of Atherosclerotic Plaques’ Iron into Nanotheranostics DOI

Wenqi Pan,

Sihui Shao,

Xinyue Cao

et al.

Journal of the American Chemical Society, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 21, 2025

The presence of a substantial necrotic core in atherosclerotic plaques markedly heightens the risk rupture, consequence elevated iron levels that exacerbate oxidative stress and lipid peroxidation, thereby sustaining detrimental cycle ferroptosis inflammation. Concurrently targeting both inflammation is crucial for effective treatment vulnerable plaques. In this study, we introduce gallium hexacyanoferrate nanoabsorption catalysts (GaHCF NACs) designed to disrupt pathological cycle. GaHCF NACs function as highly efficient chelators with robust antiferroptosis properties. Through situ capture within plaques, these enhance reactive oxygen species scavenging, initiating an amplified therapeutic response. significantly advance plaque regression, stabilization, vascular functional recovery by inhibiting MAPK13 (p38-δ MAPK) signaling, key mediator cell death. Importantly, process generates detectable photoacoustic signal, offering notable diagnostic advantage allows real-time monitoring plague status. This multifunctional nanocatalytic platform transforms toxic into agent, adapting dynamically microenvironment representing promising strategy reducing vulnerability preventing rupture.

Language: Английский

Citations

1
Inflammation in atherosclerotic cardiovascular disease: From diagnosis to treatment DOI Creative Commons
Natalie Arnold, Wolfgang Köenig

European Journal of Clinical Investigation, Journal Year: 2025, Volume and Issue: unknown

Published: March 8, 2025

Targeting inflammation offers a unique possibility to address residual cardiovascular risk in almost two thirds of all patients with prevalent atherosclerotic disease (ASCVD). However, despite FDA approval and the ESC 2024 Guidelines for Management Chronic Coronary Syndrome recommendations implement low-dose colchicine (0.5 mg daily) secondary prevention ASCVD inflammatory risk, its clinical adoption is still limited. In this regard, simple screening elevated high-sensitive C-reactive protein (hsCRP) on routine basis might help recognize low-grade as an important therapeutic target. Within present review, we first provide recently published epidemiologic evidence that hsCRP at least strong predictor future events traditional lipoproteins. Furthermore, summarize our recent knowledge currently available strategies modulate process critically discuss open issues regarding benefit therapy acute coronary setting or stroke prevention. addition, also briefly touch upon some specific safety related long-term use colchicine. Finally, next diagnostic frontiers targeting such detection vascular/coronary by pericoronary fat attenuation ziltivekimab, human monoclonal antibody interleukin-6. Thus, integration interventions aimed lowering burden combination aggressive lipid-modifying may hold potential further reduce substantial ASCVD.

Language: Английский

Citations

1
Differences in Stable and Unstable Atherosclerotic Plaque DOI
Kenji Kawai, Rika Kawakami, Aloke V. Finn

et al.

Arteriosclerosis Thrombosis and Vascular Biology, Journal Year: 2024, Volume and Issue: 44(7), P. 1474 - 1484

Published: June 26, 2024

Language: Английский

Citations

7
Colchicine for secondary prevention of ischaemic stroke and atherosclerotic events: a meta-analysis of randomised trials DOI Creative Commons

Aernoud T.L. Fiolet,

Michiel H.F. Poorthuis, Tjerk S.J. Opstal

et al.

EClinicalMedicine, Journal Year: 2024, Volume and Issue: 76, P. 102835 - 102835

Published: Oct. 1, 2024

Summary

Background

Guidelines recommend low-dose colchicine for secondary prevention in cardiovascular disease, but uncertainty remains concerning its efficacy stroke, key subgroups and about uncommon serious safety outcomes.

Methods

In this trial-level meta-analysis, we searched bibliographic databases trial registries form inception to May 16, 2024. We included randomised trials of ischaemic stroke major adverse events (MACE: myocardial infarction, coronary revascularisation, or death). Secondary outcomes were mortality. A fixed-effect inverse-variance model was used generate a pooled estimate relative risk (RR) with 95% confidence intervals (CI). This study is registered PROSPERO, CRD42024540320.

Findings

Six involving 14,934 patients prior disease included. all patients, compared placebo no reduced the by 27% (132 [1.8%] versus 186 [2.5%] events, RR 0.73 [95% CI 0.58–0.90]) MACE (505 [6.8%] 693 [9.4%] [0.65–0.81]). Efficacy consistent (females males, age below above 70, without diabetes, statin non-statin users). Colchicine not associated an increase outcomes: hospitalisation pneumonia (109 [1.5%] 106 [1.5%], 0.99 [0.76–1.30]), cancer (247 [3.5%] 255 [3.6%], 0.97 [0.82–1.15]), gastro-intestinal (153 [2.1%] 135 [1.9%]), 1.15 [0.91–1.44]. There difference all-cause death (201 [2.7%] 181 [2.4%], 1.09 [0.89–1.33]), (70 [0.9%] 80 [1.1%], 0.89 [0.65–1.23]), non-cardiovascular (131 101 [1.4%], 1.26 [0.98–1.64]).

Interpretation

MACE, treatment effect subgroups, did death.

Funding

funding source study.

Language: Английский

Citations

6
Colchicin – Phönix aus der Asche DOI Creative Commons

Raimund Lunzer,

Georg Delle‐Karth,

Markus Zeitlinger

et al.

Wiener klinische Wochenschrift, Journal Year: 2025, Volume and Issue: 137(S1), P. 1 - 33

Published: Feb. 1, 2025

Zusammenfassung Colchicin ist ein entzündungshemmender pflanzlicher Arzneistoff mit einer jahrtausendealten Geschichte. Es wird seit jeher erfolgreich in der Akuttherapie und Prophylaxe Gicht eingesetzt konnte sich einen festen Platz im pharmakologischen Standardrepertoire bei familiärem Mittelmeerfieber, Perikarditis, neutrophilen Dermatosen, Morbus Behçet oralen therapierefraktären schweren Aphthosen sichern. Rezent hat die US-amerikanische Food and Drug Administration (FDA) zugelassen, um das Risiko von Myokardinfarkt, Schlaganfall, koronarer Revaskularisation kardiovaskulärem Tod erwachsenen Patienten bestehender atherosklerotischer Erkrankung oder mehreren Risikofaktoren für eine kardiovaskuläre zu verringern. Der Empfehlungsgrad zur kardiovaskulären wurde den aktuellen ESC-Leitlinien 2024 IIb auf IIa angehoben. Klinische Studien vergangenen Jahre belegen ferner Effekt beim akuten Koronarsyndrom Vorhofflimmern. Diese Übersichtsarbeit beleuchtet Wirksamkeits- Sicherheitsprofil bietet Einblick rezente mögliche zukünftige evidenzbasierte Anwendungsgebiete.

Citations

0
Anti-inflammatory Therapies for Ischemic Heart Disease DOI Creative Commons

Tillmann Muhs,

Senka Ljubojević-Holzer, Susanne Sattler

et al.

Current Cardiology Reports, Journal Year: 2025, Volume and Issue: 27(1)

Published: Feb. 19, 2025

Abstract Purpose of Review The inclusion immunomodulatory strategies as supportive therapies in ischemic heart disease (IHD) has garnered significant support over recent years. Several such approaches appear to be unified through their ultimate target, the NLRP3 inflammasome. This review presents a brief update on continuum conditions constituting and emphasising seemingly unifying mechanism activation well modulation across these conditions. Recent Findings inflammasome is multiprotein complex assembled upon inflammatory stimulation, causing release pro-inflammatory cytokines initiating pyroptosis. pathway relevant signalling cardiac immune cells non-immune myocardium, including cardiomyocytes, fibroblasts endothelial cells. In addition focus clinical outcome efficacy trials targeting NLRP3-related pathways, potential connection between immunomodulation cardiology currently being explored preclinical trials. Colchicine, cytokine-based SGLT2 inhibitors have emerged promising agents. However, comprising IHD atherosclerosis, coronary artery (CAD), myocardial infarction (MI) cardiomyopathy/heart failure (iCMP/HF) are not equally amenable with respective drugs. Atherosclerosis, cardiomyopathy affected by chronic inflammation, but approach acute inflammation post-MI setting remains pharmacological challenge, detrimental regenerative effects initiated unison. Summary lies at center cell mediated IHD. trial evidence highlighted anti-inflammatory colchicine, interleukin-based therapy SGLT2i that drugs modulate

Language: Английский

Citations

0
Insight into the Mechanistic role of Colchicine in Atherosclerosis DOI
Hayder M. Al‐kuraishy, Ghassan M. Sulaiman, Hamdoon A. Mohammed

et al.

Current Atherosclerosis Reports, Journal Year: 2025, Volume and Issue: 27(1)

Published: March 20, 2025

Language: Английский

Citations

0
Colchicine in Coronary Artery Disease. When to Use? DOI
Daniel M. Gelfman

The American Journal of Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: April 1, 2025

Language: Английский

Citations

0